Novocure (NVCR): FDA Approves Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/5/2026

1. ZS
2. LULU
3. IOT
4. SPY
5. PATH
6. DOCU
7. ASAN
8. NVDA
9. GWRE
10. CIEN

Go back to Novocure (NVCR): FDA Approves Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer
(NASDAQ: NVCR) Delayed: 17.94 +0.30 (1.70%)
Previous Close $17.64    52 Week High $28.95 
Open $17.53    52 Week Low $5.95 
Day High $18.02    P/E N/A 
Day Low $17.47    EPS $0.00 
Volume 732,172